2021
Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review
Beroukhim G, Ozgediz D, Cohen PJ, Hui P, Morotti R, Schwartz PE, Yang-Hartwich, Vash-Margita A. Progression of Cystadenoma to Mucinous Borderline Ovarian Tumor in Young Females: Case Series and Literature Review. Journal Of Pediatric And Adolescent Gynecology 2021, 35: 359-367. PMID: 34843973, DOI: 10.1016/j.jpag.2021.11.003.Peer-Reviewed Original ResearchConceptsMucinous borderline ovarian tumorsBorderline ovarian tumorsOvarian tumorsYale-New Haven HospitalRetrospective chart reviewBenign ovarian tumorsBenign ovarian lesionsRate of recurrenceNew Haven HospitalAbdominal painPreoperative characteristicsChart reviewDisease recurrenceRecurrent cystsCase seriesChief complaintClinical presentationClinicopathologic featuresFemale patientsMucinous cystadenomaOvarian cystsOvarian lesionsTumor stageAdolescent patientsSubsequent surveillance
2020
Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
Perrone E, Lopez S, Zeybek B, Bellone S, Bonazzoli E, Pelligra S, Zammataro L, Manzano A, Manara P, Bianchi A, Buza N, Tymon-Rosario J, Altwerger G, Han C, Menderes G, Ratner E, Silasi DA, Azodi M, Hui P, Schwartz PE, Scambia G, Santin AD. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. Frontiers In Oncology 2020, 10: 118. PMID: 32117765, PMCID: PMC7028697, DOI: 10.3389/fonc.2020.00118.Peer-Reviewed Original ResearchTrop-2 expressionEOC cell linesSacituzumab govitecanEpithelial ovarian cancerPrimary tumor cell linesPreclinical activityTrop-2EOC xenograftsOvarian cancerTrophoblast cell surface antigen 2Cell linesActive metaboliteTumor cell linesImpressive anti-tumor activityCell surface antigen 2Lethal gynecologic malignancyHigh ADCC activityAnti-tumor activityParaffin-embedded tumorsSignificant bystander killingGynecologic malignanciesADCC activityEOC tissuesOvarian tumorsClinical trials
1990
Pelvic masses in pregnancy: MR imaging.
Kier R, McCarthy SM, Scoutt LM, Viscarello RR, Schwartz PE. Pelvic masses in pregnancy: MR imaging. Radiology 1990, 176: 709-13. PMID: 2389030, DOI: 10.1148/radiology.176.3.2389030.Peer-Reviewed Original ResearchConceptsSimple ovarian cystsPelvic massPregnant patientsOvarian cystsCystic massMR imagingOvarian cystic massSolid ovarian tumorCancellation of surgeryComplex cystic massMature cystic teratomaMagnetic resonance imagingPreoperative evaluationCystic teratomaOvarian cystadenomasOvarian tumorsSonographic resultsUterine fibroidsSimple cystsUrinary bladderMR imagesResonance imagingLesion characterizationMR imaging signalCysts
1984
Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro.
Lazo JS, Schwartz PE, MacLusky NJ, Labaree DC, Eisenfeld AJ. Antiproliferative actions of tamoxifen to human ovarian carcinomas in vitro. Cancer Research 1984, 44: 2265-71. PMID: 6722767.Peer-Reviewed Original ResearchConceptsEstrogen receptorFmol/Tumor samplesMicroM tamoxifenOvarian tumorsOvarian carcinomaColony formationAntiproliferative actionAntiproliferative effectsERc contentHuman epithelial ovarian tumorsSolid ovarian carcinomasERc levelsProgestin receptor levelsEpithelial ovarian tumorsDirect antiproliferative actionCombination of doxorubicinCytosolic estrogen receptorHuman ovarian carcinomaSoft agarMaximum antiproliferative effectsPRC contentsPRc levelsReceptor levelsTamoxifen